This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The influence of pregnancy on the course of multiple sclerosis (MS) has long been a topic of considerable interest to patients and health care practitioners because MS strikes most often in women of childbearing age. Until a few decades ago, women were discouraged from having a baby, fearing that pregnancy would worsen the course of disease. Since then, numerous studies have shown a reduced risk of relapse during pregnancy, followed by an increased risk of disease reactivation after delivery, most clearly revealed in a large prospective study published in 1998.1 Subsequently, the advent of the “treatment era” for MS has introduced complexity into family planning counseling and decision processes, which require additional consideration for numerous disease-modifying drugs (DMDs) before and after pregnancy. To support family planning decisions and to improve available health care services, there remains a great need for a better understanding of the natural history of MS and pregnancy in the context of an ever-expanding number of DMDs.2
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 775
See page 776
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.